Announcements Trials

Browse Landscape

Phase

Status

Completed 4 Active not recruiting 4 Unknown 2 Terminated 2 Recruiting 2 Not yet recruiting 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Oropharyngeal Neoplasms 2 Mouth Neoplasms 2 Laryngeal Neoplasms 2 Hypopharyngeal Neoplasms 2 Carcinoma 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Opioid-Related Disorders 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Leukemia, Myeloid, Acute 1 Leukemia, Biphenotypic, Acute 1 Hematologic Neoplasms 1 Colorectal Neoplasms 1 Burkitt Lymphoma 1 Breast Neoplasms 1 Barrett Esophagus 1 Advanced Cancers 1

Interventions

Paclitaxel 28 Trastuzumab 22 Cyclophosphamide 21 Doxorubicin 14 Docetaxel 14 Carboplatin 11 exemestane 10 Radiotherapy 10 Letrozole 10 Capecitabine 10 pembrolizumab 8 Lapatinib 8 Fulvestrant 8 Neoadjuvant Therapy 6 Goserelin 6 Bevacizumab 6 Anastrozole 6 pertuzumab 5 palbociclib 5 eribulin 5 abemaciclib 5 Therapeutics 5 Magnetic Resonance Spectroscopy 5 Epirubicin 5 Chemotherapy, Adjuvant 5 Aromatase Inhibitors 5 tucatinib 4 Vinorelbine 4 Taxes 4 Tamoxifen 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Breast Neoplasms × X-Rays × Clear all

NCT01714128 2021-10-25

FES-PET for Patients Treated on NCI Protocol 8762

Washington University School of Medicine

Phase NA Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡